Projects per year
Personal profile
Biography
Dr Azad is an early-career medical oncologist and translational researcher with a special interest in genitourinary malignancies.
After completing his medical oncology training and a PhD in cell biology in Melbourne, Dr Azad moved to the British Columbia (BC) Cancer Agency and Vancouver Prostate Centre, Canada for a 2-year fellowship under the supervision of Professor Kim Chi, an internationally renowned prostate cancer researcher.
At BC Cancer Agency, Dr Azad played a major role in the development of five investigator-initiated clinical trials, was actively involved in outcomes research, and led pioneering studies centred on genomic profiling of circulating cell-free DNA in advanced prostate cancer patients developing resistance to next-generation hormonal agents. The significance of Dr Azad's work with cell-free DNA was recognized by four highly prestigious Merit Awards from the American Society of Clinical Oncology and first author publications in Clinical Cancer Research and JAMA Oncology.
Dr Azad has a strong academic record including 64 publications, a patent, 11 oral presentations at national and international meetings, Poster Highlights Sessions at the 2014 and 2015 ASCO Annual Meeting, 22 competitive prizes and awards and over $4.5M in competitive funding.
In November 2015, Dr Azad commenced appointments at Monash University and Monash Health, where he is leading a clinical and translational prostate cancer research program. His ongoing research centres on circulating biomarker analysis in advanced prostate cancer patients (supported by an NHMRC Project Grant) and the predictive utility of non-coding RNA for BET inhibition in prostate cancer (supported by a Victorian Cancer Agency Translational Research Project Grant). He is also actively involved in clinical trials and notably is the lead Australian investigator for two clinical trials in advanced prostate cancer patients.
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2013 2021
Application of a multi-gene prostate circulating tumour DNA (ctDNA) panel in men with metastatic hormone- sensitive prostate cancer (mHSPC)
Southey, M. C., Kwan, E. M. K. M., Fettke, H. C. & Azad, A.
4/09/18 → 3/09/19
Project: Research
Novel targeting of therapy-resistant prostate cancer cells.
Taylor, R. A., Risbridger, G. P., Azad, A. & Nim, H. T.
1/01/18 → 31/12/20
Project: Research
A novel strategy for targeting castrate-resistant prostate cancer
Risbridger, G. P., Tilley, W. D., Furic, L., Sandhu, S. K., Azad, A., Selth, L. & Lawrence, M. G.
National Health & Medical Research Council (NHMRC)
1/01/18 → 31/12/21
Project: Research
The PRECISE assay: Personalised medicine for cancer patients using next-generation sequencing
To, S. Q. G., Azad, A., Shortt, J., Wei, A., Shackleton, M. & Kenealy, M.
1/12/17 → 1/12/20
Project: Research
The PRECISE assay: Personalised medicine for cancer patients using next-generation sequencing
1/04/17 → 1/04/19
Project: Research
Research Output 2006 2018
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy
Lawrence, M. G., Obinata, D., Sandhu, S., Selth, L. A., Wong, S. Q., Porter, L. H., Lister, N., Pook, D., Pezaro, C. J., Goode, D. L., Rebello, R. J., Clark, A. K., Papargiris, M., Van Gramberg, J., Hanson, A. R., Banks, P., Wang, H., Niranjan, B., Keerthikumar, S., Hedwards, S. & 32 others, 1 Nov 2018, In : European Urology. 74, 5, p. 562-572 11 p.Research output: Contribution to journal › Article › Research › peer-review
AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate
Todenhöfer, T., Azad, A., Stewart, C., Gao, J., Eigl, B. J., Gleave, M. E., Joshua, A. M., Black, P. C. & Chi, K. N., 1 Jan 2017, In : Journal of Urology. 197, 1, p. 135-142 8 p.Research output: Contribution to journal › Article › Research › peer-review
Molecular dissection of complete response to receptor tyrosine kinase inhibition in type II papillary renal cell carcinoma
Annala, M., Nappi, L., Azad, A. A., Mo, F., Fazli, L., Chi, K. N. & Wyatt, A. W., Feb 2017, In : Clinical Genitourinary Cancer. 15, 1, p. e145-e150 6 p.Research output: Contribution to journal › Article › Other › peer-review
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
Chi, K. N., Kheoh, T. S., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., Azad, A., Eigl, B. J. C., Heng, D., Joshua, A. M., De Bono, J. S. & Scher, H. I., 2016, In : Annals of Oncology. 27, 3, p. 454-460 7 p.Research output: Contribution to journal › Article › Research › peer-review
Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma
Day, D., Kanjanapan, Y., Kwan, E., Yip, D., Lawrentschuk, N., Davis, I. D., Azad, A. A., Wong, S., Rosenthal, M., Gibbs, P. & Tran, B., 1 Nov 2016, In : Internal Medicine Journal. 46, 11, p. 1291-1297 7 p.Research output: Contribution to journal › Article › Research › peer-review